ClinicalTrials.gg
CompletedNCT02529995AURAChinaPKUpdated Feb 11, 2020Results posted

Phase I, Study in Chinese NSCLC Patients

A Phase 1 interventional study of AZD9291 40 mg and AZD9291 80 mg in Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive, sponsored by AstraZeneca. Completed at 2 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2020-02-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Carcinoma by AstraZeneca — 1 open to participants now, 11 under way, 8 of them phase 3. Carcinoma · AstraZeneca.

Enrollment
15th of 18
31 · median 271
Started
2015
the only one that year
Phase 1
4 of 19
none open now
Registered
6th of 19
by date

Among the 19 studies in Carcinoma by AstraZeneca, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 1, and was the 6th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

1 of the 19 studies in Carcinoma by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Carcinoma by AstraZeneca, or all of them as a file.
02

Study summary

A Phase I, Open-Label, Two Parts Study to Assess the Safety, Tolerability,Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Chinese Patients with Advanced Non-Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

Study Objective: 1, Primary Objective To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550) after single then multiple doses of AZD9291 administered orally once daily in Chinese patients with locally advanced or metastatic non small cell lung Cancer (NSCLC) who have progressed following prior therapy with an approved Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) agent.

2, Secondary objective(s) To investigate the safety and tolerability of AZD9291 when given orally to Chinese patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR TKI agent. To obtain a preliminary assessment of the anti-tumour activity of AZD9291 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.

Read the detailed description

This is a phase I, open-label, two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg and 80 mg) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR TKI agent (+/- additional chemotherapy regimens).

Approximately 24 patients will enter into this study, with 12 patients at each dose level.

  • Cohort 1 will investigate the pharmacokinetics of single then multiple dosing of AZD9291 at 40 mg once daily dose.
  • Cohort 2 will investigate the pharmacokinetics of single then multiple dosing of AZD9291 at 80 mg once daily dose.

The enrollment of Cohort 2 will start after Cohort 1 finishes the enrollment. The first 12 patients enrolled in the study will be in 40 mg dose Cohort.

Patients will be administered a single dose of AZD9291 on Day 1, Cycle 0 at the beginning of Part A period. From Day 2 to Day 6, no treatment will be given, but PK samples will be obtained; on Day 7 (Cycle1, Day1), the patients will be administered AZD9291 once daily on a continuous schedule, ie, no break in AZD9291 dosing. Part A will complete after Cycle 4 treatment and Part B will start without treatment interruption.

Patients in both cohorts should continue on treatment with AZD9291 until a treatment discontinuation criterion is met. There is no maximum duration of treatment as patients may continue to receive AZD9291 beyond RECIST 1.1 defined progression as long as they are continuing to receive clinical benefit, as judged by the investigator.

The whole study will be divided nominally into two parts: Part A will assess the pharmacokinetics and preliminary efficacy and safety of AZD9291 at 40 mg and 80 mg respectively, and Part B will assess only the safety and efficacy data of AZD9291.

Following completion of the Part A, patients will automatically continue to Part B.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision
  2. Aged at least 18 years
  3. Histological or cytological confirmation diagnosis of NSCLC
  4. Locally advanced or NSCLC
  5. Radiological documentation of disease progression while on a previous continuous treatment with an approved EGFR TKI. In addition other may have been given

    • Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q)
  6. World Health Organisation (WHO) performance status 0-1
  7. At least one lesion suitable for accurate repeated measurements
  8. Females

    • Child bearing potential : should not be breast feeding, use adequate measures for female patients with , OR
    • Have evidence of non-child-bearing potential that meet one of the following criteria at screening:
    • defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
    • Women below 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution
    • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
  9. Male patients should be willing to use barrier contraception ie, condoms

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following (prior to first dose of study treatment)

    • Treatment with an EGFR TKI within 8 days
    • Any agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days
    • Previous treatment with AZD9291, or a Thr790Met (T790M) directed EGFR TKIs
    • Major surgery (excluding placement of vascular access) within 4 weeks
    • Radiotherapy :
    • Within 1 week if limited field of radiation for palliation of the first dose of study treatment
    • Within 4 weeks if receiving radiation to more than 30% of the bone marrow or with a wide field of radiation
    • Patients currently receiving (or unable to stop use at least 1 week) medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 3A4 ()
    • Treatment with an investigational drug within five half-lives of the compound
  2. Any unresolved toxicities from prior therapy greater than grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy
  3. Spinal cord compression or unless asymptomatic, stable and not requiring for at least 4 weeks prior to start of study treatment
  4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including , and (HIV). Screening for chronic conditions is not required
  5. Any of the following cardiac criteria:

    • Mean resting interval (QTc) >470 msec obtained from 3 (ECGs), using the screening clinic ECG machine derivedQTc value
    • Any abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block, second degree heart block, P wave to R wave (PR) interval >250 msec
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long (Q-T interval) QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
  6. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease 7, Inadequate bone marrow reserve or organs function as demonstrated by any of the following laboratory values:

    • \<1.5x109/L
    • count \<100x109/L
    • \<90 g/L
    • >2.5 times the (ULN) if no demonstrable liver or >5 times ULN in the presence of liver metastases
    • Aspartate aminotransferase >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
    • Total >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases
    • Creatinine >1.5 times ULN concurrent with creatinine

8, Clearance \<50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of is only required when creatinine is >1.5 times ULN nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9291 9, History of to active or inactive of AZD9291 or drugs with a similar chemical structure or class to AZD9291 10, Women who are breast feeding 11, Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site) 12, Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    AZD9291 40 mg

    Cohort 1: 40 mg once daily

    Drug: AZD9291 40 mg

  • Experimental
    AZD9291 80 mg

    Cohort 2: 80 mg once daily

    Drug: AZD9291 80 mg

Interventions

  • This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).

  • This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).

06

What researchers measure

Primary outcomes

  1. Cmax of AZD9291 After Single Dosing

    Pharmacokinetics of AZD9291 after single dosing by assessment of maximum plasma AZD9291 concentration

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  2. Cmax of AZ5104 After Single Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ5104) after single dosing by assessment of maximum plasma concentration

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  3. Cmax of AZ7550 After Single Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ7550) after single dosing by assessment of maximum plasma concentration

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  4. AUC of AZD9291 After Single Dosing

    Pharmacokinetics of AZD9291 after single dosing by assessment of area under the plasma concentration time curve from zero to infinity

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  5. AUC of AZ5104 After Single Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ5104) after single dosing by assessment of area under the plasma concentration time curve from zero to infinity

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  6. AUC of AZ7550 After Single Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ7550) after single dosing by assessment of area under the plasma concentration time curve from zero to infinity

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  7. CL/F of AZD9291 After Single Dosing

    Rate and extent of absorption of single dose AZD9291 by assessment of apparent clearance following oral administration

    Time frame: PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.

  8. C(ss, Max) of AZD9291 After Multiple Dosing

    Pharmacokinetics of AZD9291 after multiple dosing by assessment of maximum plasma concentration at steady state

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

  9. C(ss, Max) of AZ5104 After Multiple Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ5104) after multiple dosing by assessment of maximum plasma concentration at steady state

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

  10. C(ss, Max) of AZ7550 After Multiple Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ7550) after multiple dosing by assessment of maximum plasma concentration at steady state

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

  11. AUC(ss) of AZD9291 After Multiple Dosing

    Pharmacokinetics of AZD9291 after multiple dosing by assessment of area under the plasma concentration curve from time zero to the end of the dosing interval

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

  12. AUC(ss) of AZ5104 After Multiple Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ5104) after multiple dosing by assessment of area under the plasma concentration curve from time zero to the end of the dosing interval

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

  13. AUC(ss) of AZ7550 After Multiple Dosing

    Pharmacokinetics of AZD9291 metabolites (AZ7550) after multiple dosing by assessment of area under the plasma concentration curve from time zero to the end of the dosing interval

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

  14. CL(ss)/F of AZD9291 After Multiple Dosing

    Pharmacokinetics of AZD9291 after multiple dosing by assessment of apparent plasma clearance at steady state

    Time frame: PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

    Time frame: Treatment discontinuation plus 28 days or 12 months after last subject first dose (LSFD). Results are based on data cut off of 2 Nov 2016.

07

Results

Posted Mar 6, 2017

Participant flow

All patients were enrolled in China: first patient enrolled on 24-08-2015. The recruitment was closed following LSI. The primary analysis for the PK was performed at the data cut off (DCO1): 28-01-2016. The study was on-going until the final analysis for the efficacy \& safety at the data cut off (DCO2): 02-11-2016 and the study is completed.

Part A
Participant flow — Part A
MilestoneAZD9291 40mgAZD9291 80mg
Started1516
Completed00
Not completed1516
Withdrew: Ongoing study at data cut-off1416
Withdrew: Discontinued study10
Part B
Participant flow — Part B
MilestoneAZD9291 40mgAZD9291 80mg
Started1516
Completed94
Not completed612
Withdrew: Ongoing study at data cut-off07
Withdrew: Discontinued study65

Outcome measures

PrimaryCmax of AZD9291 After Single Dosing

Pharmacokinetics of AZD9291 after single dosing by assessment of maximum plasma AZD9291 concentration

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol/L
Cmax of AZD9291 After Single Dosing
nmol/LAZD9291 40mgAZD9291 80mg
Cmax of AZD9291 After Single Dosing103.8 ± 79.21195.9 ± 49.83
PrimaryCmax of AZ5104 After Single Dosing

Pharmacokinetics of AZD9291 metabolites (AZ5104) after single dosing by assessment of maximum plasma concentration

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol/L
Cmax of AZ5104 After Single Dosing
nmol/LAZD9291 40mgAZD9291 80mg
Cmax of AZ5104 After Single Dosing4.207 ± 79.859.582 ± 71.63
PrimaryCmax of AZ7550 After Single Dosing

Pharmacokinetics of AZD9291 metabolites (AZ7550) after single dosing by assessment of maximum plasma concentration

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol/L
Cmax of AZ7550 After Single Dosing
nmol/LAZD9291 40mgAZD9291 80mg
Cmax of AZ7550 After Single Dosing3.443 ± 68.427.842 ± 50.62
PrimaryAUC of AZD9291 After Single Dosing

Pharmacokinetics of AZD9291 after single dosing by assessment of area under the plasma concentration time curve from zero to infinity

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol*h/L
AUC of AZD9291 After Single Dosing
nmol*h/LAZD9291 40mgAZD9291 80mg
AUC of AZD9291 After Single Dosing6323 ± 55.8110260 ± 33.10
PrimaryAUC of AZ5104 After Single Dosing

Pharmacokinetics of AZD9291 metabolites (AZ5104) after single dosing by assessment of area under the plasma concentration time curve from zero to infinity

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol*h/L
AUC of AZ5104 After Single Dosing
nmol*h/LAZD9291 40mgAZD9291 80mg
AUC of AZ5104 After Single Dosing589.0 ± 74.201077 ± 57.22
PrimaryAUC of AZ7550 After Single Dosing

Pharmacokinetics of AZD9291 metabolites (AZ7550) after single dosing by assessment of area under the plasma concentration time curve from zero to infinity

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol*h/L
AUC of AZ7550 After Single Dosing
nmol*h/LAZD9291 40mgAZD9291 80mg
AUC of AZ7550 After Single Dosing527.4 ± 46.611292 ± 29.31
PrimaryCL/F of AZD9291 After Single Dosing

Rate and extent of absorption of single dose AZD9291 by assessment of apparent clearance following oral administration

Time frame:
PK blood samples are collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post-dose. Results are based on data cut off of 28 Jan 2016.
Reported as:
Mean · L/h
CL/F of AZD9291 After Single Dosing
L/hAZD9291 40mgAZD9291 80mg
CL/F of AZD9291 After Single Dosing14.30 ± 7.70116.45 ± 6.086
PrimaryC(ss, Max) of AZD9291 After Multiple Dosing

Pharmacokinetics of AZD9291 after multiple dosing by assessment of maximum plasma concentration at steady state

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol/L
C(ss, Max) of AZD9291 After Multiple Dosing
nmol/LAZD9291 40mgAZD9291 80mg
C(ss, Max) of AZD9291 After Multiple Dosing303.4 ± 47.96550.4 ± 32.35
PrimaryC(ss, Max) of AZ5104 After Multiple Dosing

Pharmacokinetics of AZD9291 metabolites (AZ5104) after multiple dosing by assessment of maximum plasma concentration at steady state

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol/L
C(ss, Max) of AZ5104 After Multiple Dosing
nmol/LAZD9291 40mgAZD9291 80mg
C(ss, Max) of AZ5104 After Multiple Dosing29.43 ± 46.6649.98 ± 39.73
PrimaryC(ss, Max) of AZ7550 After Multiple Dosing

Pharmacokinetics of AZD9291 metabolites (AZ7550) after multiple dosing by assessment of maximum plasma concentration at steady state

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol/L
C(ss, Max) of AZ7550 After Multiple Dosing
nmol/LAZD9291 40mgAZD9291 80mg
C(ss, Max) of AZ7550 After Multiple Dosing25.91 ± 51.7254.15 ± 31.34
PrimaryAUC(ss) of AZD9291 After Multiple Dosing

Pharmacokinetics of AZD9291 after multiple dosing by assessment of area under the plasma concentration curve from time zero to the end of the dosing interval

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol*h/L
AUC(ss) of AZD9291 After Multiple Dosing
nmol*h/LAZD9291 40mgAZD9291 80mg
AUC(ss) of AZD9291 After Multiple Dosing5698 ± 52.599570 ± 35.85
PrimaryAUC(ss) of AZ5104 After Multiple Dosing

Pharmacokinetics of AZD9291 metabolites (AZ5104) after multiple dosing by assessment of area under the plasma concentration curve from time zero to the end of the dosing interval

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol*h/L
AUC(ss) of AZ5104 After Multiple Dosing
nmol*h/LAZD9291 40mgAZD9291 80mg
AUC(ss) of AZ5104 After Multiple Dosing561.5 ± 51.74964.7 ± 37.03
PrimaryAUC(ss) of AZ7550 After Multiple Dosing

Pharmacokinetics of AZD9291 metabolites (AZ7550) after multiple dosing by assessment of area under the plasma concentration curve from time zero to the end of the dosing interval

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Geometric mean · nmol*h/L
AUC(ss) of AZ7550 After Multiple Dosing
nmol*h/LAZD9291 40mgAZD9291 80mg
AUC(ss) of AZ7550 After Multiple Dosing505.7 ± 55.231123 ± 29.05
PrimaryCL(ss)/F of AZD9291 After Multiple Dosing

Pharmacokinetics of AZD9291 after multiple dosing by assessment of apparent plasma clearance at steady state

Time frame:
PK blood samples are collected multiple times on Cycle 1 Day 8 and Cycle 2 Day 1. Results are based on data cut off of 28 Jan 2016.
Reported as:
Mean · L/h
CL(ss)/F of AZD9291 After Multiple Dosing
L/hAZD9291 40mgAZD9291 80mg
CL(ss)/F of AZD9291 After Multiple Dosing15.74 ± 8.53217.67 ± 6.072
SecondaryObjective Response Rate (ORR)

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

Time frame:
Treatment discontinuation plus 28 days or 12 months after last subject first dose (LSFD). Results are based on data cut off of 2 Nov 2016.
Reported as:
Number · % of participants
Objective Response Rate (ORR)
% of participantsAZD9291 40mgAZD9291 80mg
Objective Response Rate (ORR)46.7 (21.27 to 73.41)75.0 (47.62 to 92.73)

Adverse events

Collected over AEs from start of study drug until 28 days post treatment discontinuation or 12 months after LSFD. Results are based on data cut off of 2 Nov 2016.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9291 40mg—3/15 (20%)15/15 (100%)
AZD9291 80mg—5/16 (31.3%)16/16 (100%)
Most frequent serious events
Most frequent serious events
EventAZD9291 40mgAZD9291 80mg
BronchitisInfections and infestations1/150/16
Cerebral artery embolismNervous system disorders1/150/16
LethargyNervous system disorders1/150/16
Pancreatitis acuteGastrointestinal disorders0/151/16
Cholecystitis acuteHepatobiliary disorders0/151/16
PneumoniaInfections and infestations0/151/16
Brain oedemaNervous system disorders0/151/16
ComaNervous system disorders0/151/16
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/151/16
Pleural effusionRespiratory, thoracic and mediastinal disorders0/151/16
Most frequent other events
Showing 10 of 126
Most frequent other events
EventAZD9291 40mgAZD9291 80mg
DiarrhoeaGastrointestinal disorders5/1511/16
VomitingGastrointestinal disorders6/152/16
ParonychiaInfections and infestations0/156/16
White blood cell count decreasedInvestigations3/156/16
Dry skinSkin and subcutaneous tissue disorders5/152/16
ErythemaSkin and subcutaneous tissue disorders5/154/16
Neutrophil count decreasedInvestigations2/155/16
LeukopeniaBlood and lymphatic system disorders4/152/16
ProteinuriaRenal and urinary disorders4/152/16
RashSkin and subcutaneous tissue disorders4/151/16

Baseline characteristics

All patients enrolled who received at least one dose of AZD9291.

Age, Continuous
Age, Continuous(Years)AZD9291 40mgAZD9291 80mgTotal
Mean54.1 ± 10.7860.1 ± 10.9257.2 ± 11.10
Age, Customized
Age, Customized(Participants)AZD9291 40mgAZD9291 80mgTotal
<50 Years426
>=50-<65 Years8715
>=65-<75 Years369
>=75 Years011
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291 40mgAZD9291 80mgTotal
Female71118
Male8513
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9291 40mgAZD9291 80mgTotal
Asian/Chinese151631
08

Study locations

2 sites
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Shanghai, 200032, China
09

References and documents

Publications

  • Zhao H, Cao J, Chang J, Zhang Z, Yang L, Wang J, Cantarini M, Zhang L. Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. J Clin Pharmacol. 2018 Apr;58(4):504-513. doi: 10.1002/jcph.1042. Epub 2017 Dec 14. PubMed 29239002 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Jan 2016, 5 months.

Results were first posted in Mar 2017, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's 5 months is below that.

Counting every sponsor, half of 70 studies reached it within 46 months; a quarter within 30 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2015
First posted
Aug 20, 2015
StartActual
Aug 24, 2015
Primary completionActual
Jan 28, 2016
CompletionActual
Sep 27, 2019
Results first posted
Mar 6, 2017
Last update
Feb 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02529995
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 20, 2015
Start date
Aug 24, 2015
Primary completion
Jan 28, 2016
Completion
Sep 27, 2019
Results posted
Mar 6, 2017
Last update
Feb 11, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion